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A purine-rich intronic element enhances
alternative splicing of thyroid hormone
receptor mRNA
MICHELLE L. HASTINGS,1,2 CATHERINE M. WILSON,1,3 and STEPHEN H. MUNROE1
1Department of Biology, Marquette University, Milwaukee, Wisconsin 53201, USA
ABSTRACT
The mammalian thyroid hormone receptor gene c-erbAa gives rise to two mRNAs that code for distinct isoforms,
TRa1 and TRa2, with antagonistic functions. Alternative processing of these mRNAs involves the mutually exclusive
use of a TRa1-specific polyadenylation site or TRa2-specific 59 splice site. A previous investigation of TRa minigene
expression defined a critical role for the TRa2 59 splice site in directing alternative processing. Mutational analysis
reported here shows that purine residues within a highly conserved intronic element, SEa2, enhance splicing of TRa2
in vitro as well as in vivo. Although SEa2 is located within the intron of TRa2 mRNA, it activates splicing of a
heterologous dsx pre-mRNA when located in the downstream exon. Competition with wild-type and mutant RNAs
indicates that SEa2 functions by binding trans-acting factors in HeLa nuclear extract. Protein–RNA crosslinking
identifies several proteins, including SF2/ASF and hnRNP H, that bind specifically to SEa2. SEa2 also includes an
element resembling a 59 splice site consensus sequence that is critical for splicing enhancer activity. Mutations within
this pseudo-59 splice site sequence have a dramatic effect on splicing and protein binding. Thus SEa2 and its
associated factors are required for splicing of TRa2 pre-mRNA.
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INTRODUCTION
Alternative mRNA processing is an important mech-
anism for generating multiple mRNAs and proteins
from a single gene (reviewed in Smith & Valcárcel,
2000)+ In mammals, transcripts from the c-erbAa gene
(NR1A1; Nuclear Receptors Committee, 1999) code
for two major thyroid hormone receptor (TR) iso-
forms, TRa1 (NR1A1a) and TRa2 (NR1A1b), which
are functionally antagonistic (for a review, see Lazar,
1993)+ TRa1 is an authentic thyroid hormone recep-
tor that binds thyroid hormone (T3) and mediates its
activity in many cells and tissues+ TRa2 is a variant
receptor that lacks a functional hormone-binding site
and antagonizes the ability of TRa1 to activate gene
transcription in the presence of T3 (Koenig et al+, 1989;
Lazar et al+, 1989a)+ Although both isoforms are ex-
pressed in most mammalian cells, the levels of each
vary widely in different tissues and at different stages
of development+ Thus, regulation of TRa alternative
processing is important for determining cellular levels
of TRa1 and TRa2 mRNAs, which, in turn, are criti-
cal for modulating the response to T3+
TRa1 and TRa2 mRNAs are distinguished by their
distinct 39 terminal exons+ To produce TRa1 mRNA,
TRa pre-mRNA is cleaved and polyadenylated at the
penultimate exon (exon 9; Lazar et al+, 1989b; Laudet
et al+, 1991)+ Alternatively, TRa2 mRNA results from
use of a 59 splice site within exon 9 and ligation to an
exon (exon 10) directly downstream of the TRa1-specific
poly(A) site+ Thus, TRa2 lacks most of the TRa1 ter-
minal exon but includes an alternative 39 exon+
Alternatively processed exons often are character-
ized by suboptimal splice signals that are recognized in-
efficiently in the absence of auxiliary sequences or trans-
acting factors (for a review, see Berget, 1995; Smith &
Valcárcel, 2000)+ In the case of TRa2 mRNA splicing, a
single nucleotide deviation from the 59 splice site con-
sensus sequence is responsible for weak splicing ac-
tivity+ Mutation of the nonconsensus 15C residue in the
natural TRa2 59 splice site to a consensus 15G results
in constitutive processing of TRa2 mRNA with complete
exclusion of the TRa1 mRNAprocessing (Hastings et al+,
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2000)+ Efficient processing of such suboptimal splice
sites often requires cis-acting sequence elements, re-
ferred to as splicing enhancers, that facilitate exon rec-
ognition through interactions with the splicing machinery
(for a review, see Hertel et al+, 1997)+ Many splicing en-
hancers identified to date are purine-rich sequences lo-
cated within downstream exons+ These enhancers
interact with members of the serine-arginine (SR)-rich
family of splicing proteins and promote the use of weak
39 splice sites in the upstream intron (for a review, see
Graveley, 2000)+ The ability of individual SR proteins to
recognize specific enhancer sequences and influence
splicing in a dose-dependent manner may be an impor-
tant mechanism for regulating alternative processing+
In addition to the exonic, purine-rich elements de-
scribed above, a number of splicing enhancers are found
within introns (Gooding et al+, 1994; Huh & Hynes, 1994;
Del Gatto & Breathnach, 1995; Gallego et al+, 1997;
Wei et al+, 1997; Carstens et al+, 1998; Kosaki et al+,
1998; Lim & Sharp, 1998; Lou et al+, 1998; McCarthy &
Phillips, 1998; Chou et al+, 1999)+ The sequences of
intronic splicing enhancers identified thus far are di-
verse and often distinct from the purine-rich splicing
enhancers+ Consistent with the differences in sequence,
proteins bound to intronic splicing enhancers are usu-
ally different from the SR proteins that bind purine-rich
enhancers+ The activity of splicing enhancers may be
regulated by the nature and amount of specific RNA-
binding proteins within the cell nucleus+ Other variables
are also likely to be important, including the locations of
multiple enhancer and repressor elements, and the
strength and position of adjacent or competing process-
ing sites+ Characterization of such regulatory elements
is important for understanding the mechanisms regu-
lating alternative pre-mRNA processing+
In this study we characterize a splicing enhancer lo-
cated within the final intron of TRa2 mRNA, 130 nt
downstream of the TRa2-specific 59 splice site+ We
show that this highly conserved enhancer sequence
stimulates TRa2 mRNA splicing in vivo and in vitro and
interacts with trans-acting factors that include two abun-
dant, specifically bound proteins of 34 and 55 kDa cor-
responding to SF2/ASF and hnRNP H+ We also identify
a pseudo-59 splice site sequence within the splicing
enhancer element that is important for enhancer activ-
ity+ Our results support a model in which the intronic
element helps determine the relative levels of TRa1
and TRa2 mRNAs by enhancing the activity of the weak
TRa2-specific 59 splice site upstream+
RESULTS
Mutations in SEa2 inactivate splicing
enhancer activity
Previous analysis demonstrated that a highly con-
served sequence immediately downstream of the TRa1
coding sequence promotes TRa2-specific splicing (Hast-
ings et al+, 2000)+ These studies used a deletion mu-
tant, pErbA(DBS), that lacks all but 300 nt of the 3+7-kb
TRa2-specific intron (Fig+ 1A) and is severely defi-
cient in TRa2-specific splicing (Hastings et al+, 2000)+
Addition of 80 nt at the 59 end of the DBS deletion in
pErbA(SE80) restores efficient splicing (Fig+ 1B; Hast-
ings et al+, 2000)+ The sequence of this 80-nt splicing
enhancer element, SEa2, is very purine rich, contain-
ing 73% A and G (Fig+ 1A)+ SEa2 contains three long
uninterrupted stretches of purines (underlined in Fig+ 1A)
that resemble the GAR (R 5 purine) repeats present in
many previously characterized exonic splicing enhanc-
ers (Xu et al+, 1993; Tanaka et al+, 1994; Humphrey
et al+, 1995; reviewed in Hertel et al+, 1997)+
To determine whether the purine-rich composition of
SEa2 or, more specifically, the GAR repeats within this
region, play a role in its activity, the sequence of SE80
was disrupted by introducing two different types of mu-
tations+ First, six A-to-G and two G-to-A substitutions
were made in pErbA(SE80), replacing the alternating
G/A sequence of the GAR-like repeats in SE80 with
runs of three to five consecutive A or G residues (G/A,
Fig+ 1A)+ These substitutions resulted in a twofold de-
crease in splicing relative to the pErbA(SE80) tran-
script (Fig+ 1B, lanes 5 and 6; Fig+ 1C)+ Thus, a relatively
limited change, involving only eight purine residues near
the center of an intron nearly 300 nt long, causes a
substantial change in TRa2 splicing+ This result dem-
onstrates that the GAR repeats are important for the
function of this splicing enhancer+
An even more dramatic effect on splicing was ob-
served when G residues located throughout the 80-nt
region were changed to U residues (G/U, Fig+ 1A)+ Only
7+5% of the mRNA was spliced in transcripts containing
the SE80G/U mutation, an 80% decrease relative to
wild-type SE80 (Fig+ 1B, lanes 7 and 8; Fig+ 1C)+ Be-
cause this level of splicing is nearly identical to that of
DBS (Fig+ 1B, lanes 9 and 10), which lacks SEa2, these
G/U substitutions completely inactivate the enhancer
element+
SEa2 is required for efficient
TRa2 splicing in vitro
Next, the activity of SEa2 was examined in a system
optimized for TRa2 splicing in vitro (Munroe & Lazar,
1991)+ To this end, a series of truncated TRa tran-
scripts were prepared that contain the 59 portion of
exon 9, including the TRa2-specific 59 splice site, along
with regions from both the 59 and 39 ends of the TRa2
intron, and 250 nt of exon 10+ Transcripts containing
intron deletions identical to those of pErbA(DBS),
pErbA(SE80), and pErbA(SE80)G/U minigenes were
assayed for splicing in HeLa cell nuclear extracts
(Fig+ 2A)+ The relative splicing levels of the three pre-
cursor RNAs were comparable to those observed
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in vivo (Fig+ 2B)+ About three times as much of the
pa2(SE80) transcripts were spliced relative to pa2(DBS)
and pa2(SE80G/U) transcripts after 2+5 h+ These re-
sults demonstrate that SEa2 functions as a splicing
enhancer in vitro+
SEa2 enhances splicing of drosophila
dsx chimeric pre-mRNA
Analysis of SEa2 in vitro provides an approach for
examining SEa2 enhancer activity in the context of a
heterologous pre-mRNA+ Several exonic purine-rich
enhancers that closely resemble the sequence of SEa2
have been shown to promote splicing of exons 3 and
4 of a truncated Drosophila dsx (Fig+ 3A), that is
spliced very poorly in the absence of its own en-
hancer elements (Tian & Maniatis, 1993)+ To deter-
mine if SEa2 is functionally similar to other pur-
ine-rich enhancers, we tested mutations and length
variants of SEa2 fused to the 39 end of the truncated
exon 4 (Fig+ 3A)+
First, a dsx chimeric transcript containing SE80
(dsxSE80) was assayed for dsx splicing activity
(Fig+ 3B,C)+ As controls, an enhancerless dsx tran-
script (dsx) and a transcript that includes the strong
purine-rich splicing enhancer element from avian sar-
FIGURE 1. Mutations in SEa2 inhibit TRa2 mRNA splicing+ A: Structure of the wild-type (WT) and SE80 minigene+ Arrows
show positions of the TRa2-specific 59 splice site and polyadenylation (pA) sites for TRa1 and TRa2 and the dark box
represents the SEa2 splicing enhancer+ Vertical lines show restriction sites for Bsu36I (B) and SspI (S) that define the DBS
deletion+ Exons (boxes) are numbered from the 59 end of the c-erbAa gene+ Exons in TRa2 mRNA are thicker than the
region of exon 9 unique to TRa1+ Open boxes indicate coding regions, and hatched boxes untranslated regions+ The
sequence of the wild-type and mutant SE80 splicing enhancer is shown below+ Purine-rich GAR-like sequences are
underlined and G tracts are overlined+ B: RNase protection assays of total RNA from COS-1 cells transfected with the
indicated pErbA plasmids using a probe complementary to the TRa2-specific 59 splice site+ As a control, the probe was
hybridized with tRNA (C, lanes 11 and 12)+ Spliced (s) and unspliced (u) RNA is indicated at left+ C: Quantitation of splicing
as a fraction of spliced TRa transcript+ Histogram represents the average of at least two experiments+
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coma leukosis virus (dsxASLV; Staknis & Reed, 1994)
were tested in parallel+ As expected, dsx pre-mRNA
without a splicing enhancer was processed ineffi-
ciently (Fig+ 3B, lane 2; Fig+ 3C)+ In contrast, the pres-
ence of the ASLV enhancer resulted in an eightfold
stimulation of dsx splicing (Fig+ 3B, lane 4)+ Under
identical conditions, the addition of SE80 to dsx en-
hanced splicing more than threefold (Fig+ 3B, lane 6)+
These results show that SE80 functions as a splicing
enhancer in a heterologous pre-mRNA+
To determine if sequences between the TRa2 59
splice site and SE80 also contribute to enhancer ac-
tivity, a fragment containing an additional 80 nt up-
stream of SE80 (dsx80 1 SE80) was also tested+
This transcript was spliced at nearly equivalent levels
as dsxSE80 (Fig+ 3B, lane 10, 3C)+ This result sug-
gests that sequences upstream of SE80 do not con-
tribute to activity of SEa2, as assayed in the context
of dsx+ The specificity of SEa2 enhancer activity was
tested using the SE80G/U mutation (dsxSE80G/U;
Fig+ 3B, lanes 7 and 8) and SE80(A/G) mutation (not
shown) in the context of the dsx pre-mRNA+ Replace-
ment of SE80 with SE80G/U in the dsx chimeric tran-
script resulted in a nearly eightfold decrease in splicing
(Fig+ 3C)+ This result is consistent with the lack of
enhancer activity observed both in vivo and in vitro
with TRa pre-mRNAs containing this mutation+ How-
ever, the dsxSE80A/G mutation showed identical lev-
els to wild-type RNA (not shown), suggesting that in
vitro enhancement of splicing in the context of the
heterologous dsx exon does not require the GAR re-
peats of the wild-type SE80 sequence+
Trans-acting factors are required
for SEa2 activity
The activity of SEa2 in vitro suggests that trans-acting
factors present in the nuclear extract mediate enhancer
activity+ To determine whether specific interactions with
trans-acting factors are required for SEa2 activity, com-
petition experiments were performed+ If SEa2 binds
factors required for TRa2 splicing, an excess of SEa2
FIGURE 2. The splicing enhancer SEa2 stimulates TRa2 splicing in vitro+ A: In vitro splicing assays carried out in HeLa
nuclear extract+ Reaction times are indicated above the lanes+ Schematics of unspliced and spliced RNAs are shown at the
left of the panel+ B: The graph shows the time course of splicing, expressed as the fraction of spliced RNA + The numbers
are an average of 2–4 experiments with the exception of the 90- and 150-min time points, which represent one experiment+
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RNA should competitively inhibit splicing+ Splicing re-
actions containing 32P-labeled pa2(SE80) transcript
were incubated with one of three short competitor RNAs,
including wild-type and mutant forms of SE80 and an
unrelated nonspecific sequence (NS) of the same length
(Fig+ 4A)+ Addition of 25–50 nM of the wild-type SE80
competitor RNA resulted in a 30–60% decrease in splic-
ing (Fig+ 4A, lanes 3–5)+ This decrease reflects specific
competition by SE80 because addition of either the
mutant competitor, SE80G/U (Fig+ 4A, lanes 6–8) or
the nonspecific competitor RNA (Fig+ 4A, lanes 9–11)
had a smaller effect on splicing than SE80+ Even at the
highest concentration tested, with competitor present
at a 500-fold excess over the pre-mRNA, the wild-type
competitor inhibited splicing more than either the mu-
tant or nonspecific RNAs (Fig+ 4B), demonstrating the
specificity of competition by SE80+ This result indicates
that trans-acting factors in HeLa cell nuclear extracts
are required for SEa2 activity+
To determine whether the factors mediating enhancer
activity in these assays were specific for TRa2 mRNA
splicing, parallel experiments were also carried out with
a constitutively spliced b-globin transcript (Krainer et al+,
1984)+ Results of these experiments (Fig+ 4A, lanes 12–
22) indicate that SE80 and the two control RNAs inhibit
splicing of b-globin pre-mRNA at levels very similar to
that of the TRa pre-mRNA+ Thus wild-type SE80 com-
petitor RNA specifically sequesters factors that are re-
quired for constitutive as well as alternative splicing+
Proteins crosslink specifically
to SEa2 sequences
The next step was to characterize protein factors that
mediate SEa2 activity by binding specifically to SE80
RNA+ Proteins bound to radiolabeled SE80 transcripts
were crosslinked by UV irradiation following incuba-
tion in HeLa cell nuclear extract under splicing con-
ditions+ After trimming with ribonuclease and separating
by SDS-PAGE, two prominent bands were observed,
representing proteins of approximately 34 kDa and
55 kDa molecular weight (Fig+ 5A,B, lanes 1)+ Sev-
eral fainter bands, including one migrating at 22 kDa,
were also observed+ The specificity of protein cross-
linking to SEa2 was tested by pre-incubating nuclear
extract with increasing amounts of unlabeled SE80
competitor and SE80G/U competitor (Fig+ 5A)+ Under
these conditions, binding of the 55-kDa and 34-kDa
proteins was efficiently competed out by an excess
of wild-type SE80 (Fig+ 5A, lanes 2–4), but not with
SE80G/U (Fig+ 5A, lanes 5–7)+ Crosslinking of the
22-kDa protein was competed out by both specific
and nonspecific competitors, as were the other fainter
bands+ Interestingly, the 34-kDa and 22-kDa proteins
were crosslinked in both nuclear extract and SR pro-
tein containing reactions (Fig+ 5B, lanes 1–3), but not
in S100 extract (Fig+ 5B, lane 6)+ Because SR pro-
teins are depleted in S100 extract (Krainer & Mania-
tis, 1985), this result suggests that the 22-kDa and
34-kDa proteins represent SR proteins+ SF2/ASF is
one possible candidate for the 34-kDa protein be-
cause it is abundant in the SR fraction, migrates at
the expected position and is efficiently crosslinked to
SE80 (Fig+ 5B, lanes 4 and 5; cf+ Fig 6A)+ In contrast,
crosslinking of the 55-kDa band was observed in the
nuclear and S100 extracts, but not in the SR protein
fraction (Fig+ 5B, cf+ lanes 1 and 6 to 2 and 3)+ There-
fore, the 55-kDa protein does not appear to be an
SR protein+
FIGURE 3. SEa2 stimulates dsx pre-mRNA splicing+ A: Diagram of
the dsxSE80 chimeric transcripts+ SE80, SE80 with G/U mutations
(as in Fig+ 1), and an extended SEa2 with additional 59 sequences
(801SE80) were inserted downstream of the dsx minigene+ B: In
vitro splicing assays carried out for 90 min in HeLa nuclear extract+
The dsx without an insert (2, lanes 1 and 2) and the dsx with a strong
splicing enhancer (ASLV, lanes 3 and 4) were also included+ Reac-
tion products are shown schematically at right+ Open arrowheads
indicate unspliced RNA and black arrowheads show spliced prod-
ucts+ C: Graphical representation of splicing activity+
TRa2 splicing enhancer 863
SF2/ASF and hnRNP H bind
specifically to SEa2
As a second approach to identifying proteins that in-
teract with SEa2, northwestern blotting was performed+
The radiolabeled SE80 probe bound primarily to the
34-kDa band in the SR protein fraction (Fig+ 6A, top
panel, lane 3)+ Western blotting carried out in parallel
with northwestern blots showed that the 34-kDa band,
the most intense band in the SR fraction, comigrated
with SF2/ASF (Fig+ 6A, bottom panel, lane 3)+ Recom-
binant SF2/ASF, which migrates substantially faster than
endogenous SF2/ASF due to its lack of phosphoryla-
tion (Krainer et al+, 1991), also bound labeled SE80
probe (Fig+ 6A, bottom panel, lane 4)+ A faint band co-
migrating with SF2/ASF was also visible in the nuclear
extract (Fig+ 6A, bottom panel, lane 1)+Additional north-
western blots demonstrated that labeled SE80(G/U)
did not bind SF2/ASF or proteins in the SR fraction (not
shown)+ Also, recombinant SC35, another SR protein
that comigrates with SF2/ASF, failed to bind SEa2 un-
der conditions where SF2/ASF bound efficiently (Fig+ 6A,
bottom panel, lane 5)+ The relative intensities of the
bands in nuclear extract and SR fraction reflect the
substantially higher concentration of SR proteins in the
latter, as can be seen by comparing the corresponding
lanes in the northwestern and western blots (Fig+ 6A,
lanes 1 and 3)+ The labeled SE80 probe also bound to
a 90-kDa protein present in nuclear extract but not SR
protein fraction (Fig+ 6A, top panel, lanes 1–3)+ The
55-kDa protein that is efficiently crosslinked to SE80
apparently binds SE80 inefficiently under blotting con-
ditions+ However, a faint band in the 55-kDa region was
detected upon longer exposures (not shown)+
Immunoprecipitation experiments were carried out to
confirm the binding of SF2/ASF to SE80 and to identify
FIGURE 4. Inhibition of TRa2 mRNA splicing in vitro by competition with SE80 RNA+ A: HeLa nuclear extract was pre-
incubated without competitor RNA (lanes 2 and 13) or with 25, 50, or 100 nM of the unlabeled competitor SE80 (lanes 3–5
and 14–16), SE80G/U (lanes 6–8 and 17–19), or a nonspecific RNA (NS, lanes 9–11 and 20–22)+ After preincubation, either
pa2-SE80 pre-mRNA (lanes 1–11) or b-globin pre-mRNA (lanes 12–22) was added at a concentration of 0+2 nM and the
incubation was continued for an additional 90 min, except for two reactions collected immediately (lanes 1 and 12) to show
unspliced substrate+ Open arrows indicate precursor RNA and black arrows show spliced products+ B: Percentage of
splicing, normalized to 100% in the absence of competitor RNA, is shown as a function of competitor concentration+ Left
panel shows splicing of pa2SE80 pre-mRNA and right panel splicing of b-globin pre-mRNA+ Competitor RNAs with long
flanking sequence were used and are indicated as circles: SE80; squares: SE80G/U; and triangles: nonspecific RNA+
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FIGURE 5. Nuclear proteins crosslinking to SE80+ A: Protein crosslinking to 32P-labeled SE80 RNA in HeLa cell nuclear
extract with or without (lane 1) an excess of wild-type (lanes 2–4) or G/U mutant (lanes 5–7) unlabeled SE80 competitor
RNA with short flanking sequence+ Molecular weight markers are shown at the left of the panel+ B: Crosslinking of proteins
in nuclear extract (lane 1), HeLa SR proteins (lane 2, 150 ng; lane 3, 300 ng), recombinant SF2/ASF (rSF2; lane 4, 60 ng;
lane 5, 120 ng), and S100 extract (lane 6) to labeled SE80 RNA with long flanking sequence+Arrowheads in A and B indicate
three abundant proteins of 22, 34, and 55 kDa+
FIGURE 6. Binding of SF2/ASF, hnRNP H, and hnRNP F to SE80+ A: Analysis of proteins binding to SE80+ Upper panel:
Northwestern blot of proteins binding SE80+ Samples of nuclear extract (NE, lane 1), S100 extract (lane 2), HeLa SR
proteins (lane 3, 0+6 mg), recombinant SF2/ASF (lane 4, 0+1 mg), and SC35 (lane 5, 0+1 mg) were analyzed by SDS-PAGE,
blotted, and probed with 32P-labeled SE80 RNA+ Lower panel: Parallel western blot analysis of gel run with the same
samples+ The blot was developed with SF2/ASF-specific antibody+ The migration of endogenous, phosphorylated SF2/ASF
(hSF2) from HeLa cells and recombinant, nonphosphorylated SF2/ASF are indicated at the right on both panels+ B: Im-
munoprecipitation of crosslinked proteins with SF2/ASF-specific antibody+ SE80 was incubated in nuclear extract under
splicing conditions for 30 min and then UV crosslinked+ Input lane (lane 1) represents 8% of the UV-crosslinked splicing
reaction, which was subsequently immunoprecipitated with an SF2/ASF-specific antibody (lane 2) or a control antibody
(lane 3)+ Proteins were resolved by SDS-PAGE on a 12% gel+ C: Immunoprecipitation of labeled SE80 with hnRNP H- and
F-specific antibodies+ Input lanes at two exposures (lanes 1 and 2) are 4% of the reaction that was used in the immuno-
precipitations using polyclonal antibodies specific for hnRNP H (lane 3), or hnRNP F (lane 4), or preimmune serum (lane 5)+
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the 55-kDA crosslinked protein+ As shown in Figure 6B,
SF2/ASF, labeled by UV crosslinking to SE80, was spe-
cifically precipitated with a monoclonal antibody spe-
cific for SF2/ASF (lane 2), but not by antibodies prepared
in a similar fashion to a control antigen (lane 3)+ A
similar approach was used to identify the abundant
55-kDa protein+ Because this protein is present in the
S100 extract but not the SR protein preparation, pos-
sible candidates include hnRNP F or hnRNP H, two
closely related RNA-binding proteins that are known to
bind to splicing regulatory elements (Chen et al+, 1999;
Chou et al+, 1999; Fogel & McNally, 2000)+ As shown in
Figure 6C, a polyclonal antibody specific for hnRNP H
(Chou et al+, 1999) efficiently precipitated a 55-kDa
crosslinked protein comigrating with the most intense
input band, thereby confirming that hnRNP H was cross-
linked to SE80 (Fig+ 6B, lane 3)+ A polyclonal antibody
that specifically recognizes hnRNP F precipitated a small
amount of crosslinked hnRNP F that migrates immedi-
ately below hnRNP H (Fig+ 6B, lane 4)+ On the basis of
these results, we conclude that SF2/ASF and hnRNP
H are two of the major proteins that bind to SEa2+
A 59 splice site-like sequence is required
for SEa2 activity
To further analyze the role of specific sequences and
proteins required for the function of SEa2, a series of
deletion mutations was constructed, transfected into
HEK 293 cells, and analyzed by RNase protection
assays using the TRa2 59 splice site-specific probe
(Fig+ 7A)+ SE70, SE60, SE50, and SE40 contain de-
letions of 10–39 nt from the 59 end of SE80+ SE80D30
contains a deletion of 30 nt spanning the coding se-
quence for the last 10 amino acids of TRa1, imme-
diately upstream of the 59 end of SE80 (Fig+ 7A)+
SE60/39 contains a deletion of 20 nt from the 39 end
of the SE80 enhancer+ The splicing of SE80D30 and
SE70, containing deletions upstream and at the 59
end of SE80, respectively, is about 90% that of SE80,
demonstrating that sequences more than 10 nt down-
stream of the Bsu36I site account for most of the
enhancer activity (Fig+ 7B, lanes 1–3)+ A 20-nt dele-
tion from either end of the enhancer fragment in SE60
and SE60/39 had a significant effect on splicing, with
a 25% and 33% decrease, respectively, relative to
SE80 (Fig+ 7B, lanes 4 and 7)+ Deletions of 30–40 nt
from the 59 end of SE80 had a much more drastic
effect on splicing as seen with SE50 and SE40, which
are spliced at a level only 20–40% that of the full-
length SE80 (Fig+ 7B, lanes 5 and 6)+ Previous re-
sults further showed that deletion of 50 nt from the 59
end of SE80 eliminates splicing enhancer activity
(Hastings et al+, 2000)+ The substantial but partial loss
of enhancer activity seen with the deletion of 20 nt
from either end of the enhancer (Fig+ 7, lanes 1, 4,
and 7) and with the SE80G/A substitutions (Fig+ 1C)
strongly suggests that the SEa2 splicing enhancer
comprises multiple elements that interact to promote
splicing of TRa2 mRNA+
FIGURE 7. Deletion analysis of SEa2 splicing enhancer+ A: Se-
quences of deletions in SE80+ Positions of TRa1 stop codon and
restriction sites defined previously (Fig+ 1A) are indicated+ G runs are
overscored and GAR repeats are underlined+ B: Results of RNase
protection assays using the TRa2 59 splice site probe to evaluate
splicing of total RNA from HEK 293 cells transfected with the indi-
cated minigenes+ RNA from untransfected control cells (C) is also
shown+ The histogram is based on results of three to seven assays,
representing three to five independent experiments for each con-
struct+ Error bars indicate 6 standard deviation+
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Further analysis focused on the dramatic drop in splic-
ing enhancer activity between SE60 and SE50, which
differ by only 9 nt (Fig+ 7A,B, lanes 4 and 5)+ This region
at the 59 end of SE60 includes the sequence CTG
GTGGGG (Fig+ 8A, top), which closely resembles the
mammalian 59 splice site consensus sequence (CAG/
FIGURE 8. Mutations in SE60 alter TRa2 splicing+ A, top: Sequence of enhancer region in mutated TRa2 substrates+
Location of the 59-splice-site-like sequence is shaded+ Slash (/) indicates putative cryptic 59 splice site cleavage+ Left panel:
RNase protection assays carried out as described in Figure 7B with indicated mutations+ Unspliced (u) and spliced (s)
products are indicated+ Right panel: RT-PCR analysis of total RNA isolated from wild-type and mutant SE60+ A control PCR
reaction (C) provides a marker for unspliced product (u)+ The sequence of the middle RT-PCR product band indicating
cryptic splicing (/) of SE60(16U) is shown at right+ B: RNase protection assays carried out with SE60 RNA mutations+
C: Histogram of TRa2 splicing of wild-type and mutant SE60 RNA+ Solid bars indicate the sole use of the TRa2 59 splice
site and hatched bars indicate RNAs that are also spliced at the cryptic 59 splice site+ Results are based on two experiments
and three determinations, except for SE40, which is only one determination+
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GTRAGT)+ Additional mutations were made to deter-
mine whether this 59-splice-site-like sequence is func-
tionally important+ Three nucleotides, GGT, which
represent the most highly conserved portion of the 59
splice site consensus sequence, were replaced with
CCA (SE6021CCA; 21 indicating the position of the
59 nucleotide relative to its position in the 59 splice site
consensus sequence; cf+ Fig+ 8A) to weaken any
possible interactions with splicing factors+ Conversely,
the final G residue was replaced with a T to improve
its match to the 59 splice site consensus sequence
(SE6016U) (Fig+ 8A)+ If this sequence functions by bind-
ing splicing factors that promote TRa2-specific splic-
ing, the SE6021CCA mutation should disrupt enhancer
activity+ On the other hand, if the 59-splice-site-like se-
quence interacts directly with active splicing factors,
the 16U mutation might either increase splicing at the
normal site or promote cryptic splicing by creation of a
strong 59 splice site+
The effects of these two mutations, as analyzed by
RNase protection assays, indicate that both alter-
ations cause a strong decrease in splicing at the TRa2-
specific 59 splice site (Fig+ 8A, left panel, lanes 1–3)
to 25–30% of that observed for the wild-type SE60+
RT-PCR (Fig+ 8A, right panel, lanes 2 and 3) was
used to assay for normal and cryptic splicing of the
transcripts+ Although the 21CCA mutation showed only
the expected decrease in normal splicing, RT-PCR
amplification of SE6016U RNA showed the presence
of a novel band that was intermediate in length
between the TRa2 unspliced and spliced products
(Fig+ 8A, right panel, lane 4)+ Sequencing of the iso-
lated product confirmed that the cDNA represents a
novel transcript in which the 59-splice-site-like se-
quence within SE60 is spliced precisely to the TRa2-
specific 39 splice site (Fig+ 8A)+ Taken together, these
results strongly suggest that the 59-splice-site-like se-
quence (subsequently referred to as the pseudo-59
splice site) is important for efficient TRa2 splicing+
Interestingly, the level of TRa2-specific splicing ob-
served with the 21CCA mutation was consistently
less than that seen with SE50 (Fig+ 8A, lane 4)+
To further investigate the role of this pseudo-59 splice
site element, additional mutations were made contain-
ing replacements of 1 to 3 nt+ Several mutations were
targeted at positions corresponding to the most highly
conserved nucleotides in the consensus 59 splice site+
Single and double nucleotide substitutions at positions
11 and 12 of the pseudo-59 splice site (11CA and
11C) targeted the highly conserved GT dinucleotide+
Each of these was nearly as effective as the 3-nt sub-
stitution 21CCA (Fig+ 8C)+ When the three consecutive
G residues at positions 13 to 15 within the pseudo-59
splice site consensus sequence were replaced with U
residues (13UUU), splicing activity also was reduced
nearly to the same level as with the 21CCA (Fig+ 8B,
lanes 5 and 9)+ Furthermore, increasing the match to
the 59 splice site by replacing G residues at positions
13 and 14 with A residues (13AA; Fig+ 8B, lane 8)
strongly activated cryptic splicing (Fig+ 8B, lane 8, and
results not shown)+ These results demonstrate that the
sequences included within the pseudo-59 splice site
are important for TRa2-specific splicing+
To determine if nucleotides immediately upstream
of the pseudo-59 splice site in SE60 are also essen-
tial for TRa2 splicing, two additional substitutions were
examined+ One substitution, 24AAA, that overlaps the
23 and 22 positions of the pseudo-59 splice site re-
duced normal splicing (Fig+ 8B, lane 3) but activated
cryptic splicing (result not shown)+ Further analysis
showed that replacement of only a single nucleotide
in this region (22A) was sufficient for activation of
cryptic splicing (Fig+ 8B, lane 4, and result not shown)+
However, another upstream substitution, 25CU, that
did not overlap any part of the 59 splice site consen-
sus sequence, resulted in only a modest (30%) de-
crease in splicing relative to the substitutions studied
in the pseudo-59 splice site itself (Fig+ 8B, lane 2,
Fig+ 8C)+ This mutation replaces the AG dinucleotide
in the center of the sequence (27)GGAGCTG that
resembles a motif (GGGGCTG) important for the ac-
tivity of other intronic splicing enhancers (Carlo et al+,
1996; Carstens et al+, 1998)+ Thus, it appears that
the pseudo-59 splice site is more important than the
GGAGCTG element in SEa2+ Based on these re-
sults, we conclude that the pseudo-59 splice site at
the 59 end of SE60 (Fig+ 8A) is critically important for
the splicing enhancer activity of SEa2+
Mutations in SEa2 that block splicing also
decrease protein crosslinking
The enhancer sequences corresponding to the 59 de-
letions described above were compared to SE80 for
their ability to crosslink proteins in HeLa cell nuclear
extract+ As shown in Figure 9A, lanes 1 and 2, SE60
and SE80 crosslink a similar complement of proteins
with the exception of smaller proteins below 22 kDa+ In
contrast, both the 55- and 34-kDa proteins crosslink to
SE50, SE40, and SE6021CCA to a much lesser extent
(Fig+ 9A, lanes 3–5)+ Significantly, the SE6016U mu-
tation does not affect the crosslinking efficiency to the
34- and 55-kDa proteins (Fig+ 9A, lanes 2 and 6)+ Thus,
the presence of a functional 59 splice site in this frag-
ment does not alter its interaction with these proteins+
To confirm that hnRNP H is specifically bound to
SE60 but not SE6021CCA, splicing reactions con-
taining nuclear extract and labeled RNA were cross-
linked, and bound proteins were immunoprecipitated
with an hnRNP H-specific antibody+ As seen in Fig-
ure 9B, hnRNP H crosslinked more efficiently to SE60
than to SE6021CCA (lanes 3 and 7)+ A polyclonal
antibody specific for hnRNP F also precipitated a small
amount of hnRNP F, migrating slightly ahead of hnRNP
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H, which crosslinked specifically to the wild-type SE60
(Fig+ 9B, lanes 2 and 6)+ These results show that
deletions and mutations that strongly reduce the ac-
tivity of the splicing enhancer also significantly re-
duce the crosslinking of proteins binding specifically
to the purine-rich element+
DISCUSSION
Regulation of TRa2 RNA splicing is important for de-
termining the balance between TRa1 and TRa2, two
functionally antagonistic transcription factors encoded by
the erbAa gene+ In this study, we show that a cis-acting
element, SEa2, located downstream of the TRa2-
specific 59 splice site, enhances splicing both in vivo and
in vitro+ This element contains several purine-rich ele-
ments similar to those found in many splicing enhanc-
ers as well as a pseudo-59 splice site+ SEa2 is different
from most purine-rich enhancer elements in its intronic
location (Hastings et al+, 2000)+ We also find that SF2/
ASF, hnRNP H, and hnRNP F interact with SEa2 and that
mutations in SEa2 that weaken these interactions
strongly reduce the enhancer activity of SEa2+
Purine-rich elements are required
for SEa2 activity
SEa2 is extremely purine rich and contains multiple
copies of two motifs that have been described in other
splicing enhancers+ First, three uninterrupted stretches
of purine residues (underlined in Fig+ 1A), that include
repeats of the trinucleotide GAR, are important for splic-
ing+ When these GAR repeats were altered by eight
purine–purine substitutions, a 50% decrease in splic-
ing activity was observed+ This result is consistent with
other studies showing that tandem repeats of GAR are
essential for enhancer activity (Xu et al+, 1993; Tanaka
et al+, 1994; Humphrey et al+, 1995)+
A second type of purine-rich element in SEa2 con-
sists of several consecutive G residues (overlined in
Fig+ 1A)+ Such G tracts have been found within introns
close to intron/exon junctions (Nussinov, 1988; Mc-
Cullough & Berget, 1997, 2000)+ Consecutive G resi-
dues are found in certain sequence motifs present in
other intronic enhancers including two, GGGGCUG and
(A/U)GGG (Sirand-Pugnet et al+, 1995;Carlo et al+, 1996;
Carstens et al+, 1998) that are also present in SEa2+ Be-
cause four of the five G tracts within SEa2 are disrupted
in SE80G/U, which lacks enhancer activity, these ele-
ments may also be essential for SEa2 function+ Further
deletion and substitution mutations demonstrate that se-
quences other than the GAR repeats are important for
enhancer function+ However, the G/A substitutions dis-
rupt the GAR repeats while extending, not disrupting, two
overlapping runs of three consecutive G residues in
SEa2+ Thus, the GAR repeats themselves may be
needed for full enhancer function+
The location of SEa2 within an intron and its function
in promoting upstream 59 splice site activity are un-
usual for a purine-rich enhancer, the majority of which
are located within exons downstream of the 39 splice
site on which they act (reviewed in Hertel et al+, 1997)+
FIGURE 9. SEa2 mutations alter protein crosslinking+ A: Crosslinking of proteins to indicated 32P-labeled RNAs was
carried out as in Figure 5+ B: Immunoprecipitation of crosslinked proteins with polyclonal antibodies specific for hnRNP H
(lanes 3 and 7) and hnRNP F (lanes 2 and 6)+ Nuclear proteins were crosslinked to labeled SE60 (lanes 1–4) or SE6021CCA
(lanes 5–8) RNA with no flanking sequences followed by immunoprecipitation+ Proteins were resolved by SDS-PAGE on a
10% gel+
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Both the sensitivity of SEa2 to the G/A substitutions
and its ability to enhance splicing of the heterologous
dsx pre-mRNA are consistent with characteristics pre-
viously noted for purine-rich exonic enhancers (Hum-
phrey et al+, 1995)+ The juxtapositioning of elements
characteristic of both exonic and intronic splicing en-
hancers in SEa2 is consistent with the growing body of
evidence that splicing enhancers are composite ele-
ments comprised of multiple sites for binding a variety
of trans-acting factors (Hertel et al+, 1997)+
SR proteins interact with SEa2
Inhibition of TRa2 splicing by excess wild-type com-
petitor but not mutant transcripts suggests that SEa2
function requires sequence-specific binding of trans-
acting factors in HeLa nuclear extract+ RNA–protein
crosslinking reveals that 55-kDa, 34-kDa, and 22-kDa
proteins bind to SEa2 (Fig+ 5A)+ Both the 22-kDa and
34-kDa proteins appear to be SR proteins (Fig+ 5B)+
There is a single well-characterized SR protein of 20 kDa
(SRp20) and at least four SR proteins that migrate at
about 34 kDa (SF2/ASF, SC35, 9G8, or SRp30c; re-
viewed in Graveley, 2000)+ SF2/ASF is at least one of
the proteins interacting with SEa2, as indicated by UV
crosslinking, immunoprecipitation, and northwestern blot
analysis (Figs+ 5B and 6A)+ Binding of the 22-kDa pro-
tein is competed by both the wild-type and SE80G/U
competitor RNA (Fig+ 5A)+ Although this result may in-
dicate nonspecific binding, the protein also crosslinks
much less efficiently to SE60 than to SE80 (Fig+ 9A),
suggesting that the 22 kDa protein may be associated
with the 59 end of SE80, which is absent in SE60 and
unchanged in SE80G/U+
SR proteins have been shown to mediate the activity
of other purine-rich exonic splicing enhancers (reviewed
in Graveley, 2000)+ Consistent with this role in splicing,
enhancer sequences have been shown to contain con-
sensus sequences recognized by a number of SR pro-
teins (Liu et al+, 1998; Tacke & Manley, 1999)+ SE80
contains an unusually high density of potential SF2/ASF
interacting sites (not shown) as determined by sequence
analysis with a score matrix generated by selection for
SF2/ASF-dependent enhancer sequences in vitro (Liu
et al+, 1998)+ SEa2 also includes two GGACAA se-
quences that were identified as SF2/ASF-dependent en-
hancers in b-globin (Schaal & Maniatis, 1999)+This may
explain the inhibition of b-globin splicing in the pres-
ence of SEa2 competitor RNA (Fig+ 4)+ In addition, both
the SE80G/A and SE80G/U mutations alter potential
SF2/ASF interactions+ Thus, it is likely that SF2/ASF
plays a role in mediating enhancer activity of SEa2+
The requirement for SR proteins in mediating the
enhancer activity of SEa2 was further investigated
by adding recombinant SF2/ASF to splicing reactions
preincubated with SE80 competitor RNA+ Increasing
amounts of SF2/ASF relieved the competition (not
shown)+ This result supports the model in which SF2/
ASF promotes splicing through its association with
the SEa2 enhancer+ However, because SF2/ASF
added to control reactions without competitor also stim-
ulated splicing of the SE80 transcript, it is not possi-
ble to resolve completely the roles of SF2/ASF in
basal splicing and in SEa2 enhancer-mediated splicing+
hnRNP H and hnRNP F interact with SEa2
Like the 55-kDa crosslinked protein, both hnRNP F
and hnRNP H proteins are present in S100 and nu-
clear extract but not in the SR protein preparation,
migrate between 50 and 60 kDa, and bind G-rich in-
tronic splicing enhancer elements (Matunis et al+, 1994;
Chou et al+, 1999)+ We confirmed this interaction by
antibody-specific immunoprecipitation of hnRNP H and
F crosslinked to SE80+ The intense 55-kDa band cor-
responds to hnRNP H whereas hnRNP F comigrates
with a much fainter band just in front of hnRNP H
(Figs+ 6C and 9B)+ Although this result may simply
reflect differences in the efficiency of crosslinking and
immunoprecipitation, it is likely that hnRNP H is the
major protein species bound to SEa2 and that hnRNP
F binds to only a relatively small fraction of SEa2
transcripts+ SE60, which displays a high level of splic-
ing enhancer activity (Fig+ 7B), also binds hnRNP H
and F (Fig+ 9B), whereas SE6021CCA, SE50, and
SE40, which lack significant splicing enhancer activ-
ity, do not bind efficiently to hnRNP H+ Thus, inter-
actions of SEa2 with hnRNP H and F correlate with
splicing enhancer activity, suggesting that these pro-
teins are involved in SEa2 function+
hnRNP H and hnRNP F have been shown to activate
neural-specific splicing of c-src mRNA (Min et al+, 1995;
Chou et al+, 1999)+ This enhancer sequence is located
in the intron downstream of the regulated exon+ The
Rous sarcoma virus (RSV) primary RNA transcript also
contains an intronic element, NRS, that interacts
with hnRNP H to regulate splicing (Fogel & McNally,
2000)+ However, in this case, hnRNP H mediates NRS-
dependent splicing inhibition+ hnRNP H is also impli-
cated in the inhibition of rat b-tropomyosin splicing (Chen
et al+, 1999)+ As observed with the c-src enhancer,
hnRNP H bound to SEa2 may promote TRa2 splicing+
Inhibition or enhancement of splicing by hnRNP H does
not appear to be determined by the location of the reg-
ulatory sequences but is likely to be influenced by spe-
cific interactions with other factors+
A pseudo-59 splice site sequence is
critical for SEa2 activity
Deletion analysis of SEa2 showed that the 9-nt region
present in SE60 but not SE50 overlaps a 59-splice-site-
like sequence that is essential for SEa2 activity (Fig+ 7)+
Interestingly, two single nucleotide substitutions (22A
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or 16U) at relatively peripheral sites, as well as other
substitutions that increase the match to the consensus
59 splice site (SE6024AAA, SE6012AA), activate ef-
ficient cryptic splicing at this site+ This cryptic splicing
does not occur in wild-type pre-mRNAs and thus the
sequence represents a pseudo-59 splice site+
The importance of this site in SEa2 enhancer ac-
tivity was demonstrated by additional mutations+
SE6011C RNA, which has a single base substitution
in the pseudo-59 splice site sequence at one of the
most highly conserved positions in the consensus 59
splice site, severely blocks splicing at the TRa2 59
splice site (Fig+ 8)+ However, it does not appear that
this pseudo-59 splice site is entirely responsible for
SEa2 activity, as other substitutions (SE80A/G, SE60-
5CU) and deletions (SE60 and SE60/39) within SEa2
that do not affect this sequence also reduce TRa2
mRNA splicing+
Pseudo-59 splice sites have been identified within
elements regulating alternative processing in other tran-
scripts+ Pseudo-59 splice sites located in the drosophila
P element (Siebel et al+, 1992) and Rous sarcoma virus
(Gontarek et al+, 1993) mediate inhibition of alternative
splicing, whereas one in calcitonin/CGRP mRNA acti-
vates alternative polyadenylation at an upstream site
(Lou et al+, 1995)+ Each of these sites has been shown
to interact with U1 snRNP (Siebel et al+, 1992; Lou
et al+, 1998; Hibbert et al+, 1999; McNally & McNally,
1999)+ However, in no other instance is a pseudo-59
splice site sequence associated with the activation of
splicing as it is in SEa2+ Recently, intronic G triplets
present in a-globin pre-mRNA have been shown to bind
U1 snRNPs and enhance splicing at an upstream 59
splice site, indicating that U1 snRNP binding within an
intron can stimulate splicing (McCullough & Berget,
2000)+ The role of the SEa2 pseudo-59 splice site in
activating splicing of TRa2 pre-mRNA is reminiscent of
the ability of the 59 splice site of a downstream intron to
stimulate splicing of an upstream intron, an activity
ascribed to exon definition (Robberson et al+, 1990)+
However, because the intronic pseudo-59 splice site
sequence appears to promote the use of an upstream
59 splice site rather than an upstream 39 splice site, as
in traditional exon definition, the mechanism by which it
promotes splicing is likely distinct+ Thus, the pseudo-59
splice site present in SEa2 provides an unusual exam-
ple of the ability of 59-splice-site-like sequences to ac-
tivate splicing at a distance+
Models for SEa2 splicing enhancer activity
One model for SEa2 function is that factors interacting
with a pseudo-59 splice site promote the binding of
other hnRNP and SR proteins which, in turn, promote
use of the TRa2-specific 59 splice site upstream+ The
SE6021CCA mutation may abrogate associations with
factors such as U1 snRNP binding to the pseudo-59
splice site, and thereby weaken interactions of proteins
such as SF2/ASF and hnRNP proteins with neighbor-
ing sites in the enhancer+ In this model, the pseudo-59
splice site serves as a recruitment or assembly site for
components of an enhancer-associated complex+ Al-
ternatively, SR proteins, hnRNP H and F, and other
factors may assemble at or near the pseudo-59 splice
site sequences independent of U1 snRNP binding and
stimulate assembly of other splicing factors including
U1 snRNP, which, although not active itself, is properly
situated to promote processing at the upstream TRa2-
specific 59 splice site+ Indeed, SR proteins have been
reported to stimulate U1 snRNP binding at a 59 splice
site (Kohtz et al+, 1994; Staknis & Reed, 1994; Jamison
et al+, 1995)+ These models are supported by our re-
sults that both the pseudo-59 splice site and purine-rich
region are functionally important, as neither element is
efficient in enhancing TRa2 splicing in the absence of
the other (Figs+ 1 and 8)+ Such models for SEa2 splic-
ing enhancer activity are attractive, as the balance
between TRa2 splicing and TRa1 polyadenylation is
dependent on a number of factors, including the rela-
tive strength of the TRa2-specific splice sites, the TRa1
polyadenylation site, and SEa2 (Hastings et al+, 2000;
S+H+ Munroe, M+L+ Hastings, & S+ Balthazor, unpubl+
results)+
The results presented here define an unusual in-
tronic enhancer element that is important for the alter-
native processing of mRNAs for two major isoforms of
the mammalian T3 receptor+ We have identified three
components, SF2/ASF, hnRNP F, and hnRNP H, that
interact specifically with SEa2+ Like other splicing en-
hancer elements, SEa2 appears to establish a balance
between competing processing reactions+ However, sev-
eral lines of evidence suggest that regulation of the
levels of TRa1 and TRa2 mRNA also involves selective
inhibition of TRa2 mRNA processing by a naturally oc-
curring RevErbAa antisense transcript that overlaps the
39 end of TRa2 but not TRa1 mRNA (Lazar et al+, 1988;
Hastings et al+, 2000)+ Further studies of SEa2 will pro-
vide insight into its role in the regulation of TRa gene
expression and the function of this intronic, purine-rich
splicing enhancer and its associated pseudo-59 splice
site+
MATERIALS AND METHODS
Plasmids
Construction of pErbA, pErbA(DBS), and pErbA(SE80)
has been described previously (Hastings et al+, 2000)+
pErbA(SE80)G/U, pErbA(SE80)G/A, pErbA(SE80)D30,
pErbA(SE70), pErbA(SE60), pErbA(SE50), pErbA(SE40),
pErbA(SE60/39), pErbA(SE60)CCA, and pErbA(SE60)G/T
were constructed from pErbA(SE80) or pErbA(SE60) by
PCR using primer sets containing the desired mutations in
addition to the Bsu36I and XbaI restriction sites flanking
TRa2 splicing enhancer 871
the 80-nt enhancer+ The sequences of the specific inserts in
these constructs are shown in Figures 1A, 7A, and 8A+
pErbA(SE80)DHB and pErbA(SE80)G/UDHB were con-
structed by cutting pErbA(SE80) and pErbA(SE80)G/U, re-
spectively, with HindIII and Bsu36I, and religating the vectors
after end filing to delete the 59 end of the minigene insert+
Plasmids used for production of pre-mRNA in vitro splicing
substrates were derived from plasmid pa2-S (Munroe & Lazar,
1991)+This plasmid contains the same deletion as pErbA(DXS)
(Hastings et al+, 2000) but lacks intron 8 and sequences up-
stream of the Pst I site in exon 8 and downstream of the
EcoRI site in exon 10+ pa2(DBS) contains the same deletion
as described for pErbA(DBS) (Hastings et al+, 2000)+
pa2(SE80) and pa2(SE80)G/U were constructed by insert-
ing the sequences found between the Bsu36I and XbaI sites
in pErbA(SE80) and pErbA(SE80)G/U, respectively, between
the same sites in pa2(DBS)+ Plasmids pDsx-ASLV (Staknis &
Reed, 1994) and pDsx modified by insertion of XbaI and
KpnI cloning sites in two different orientations (McNally &
McNally, 1998) have been previously described+ The latter
two pDsx vectors are referred to as pDsx-X/K and pDsx-K/X,
depending on the order of the XbaI (X) and KpnI (K) sites
in the polylinker region adjacent to dsx exon 4+ The dsx
plasmids were the generous gift of R+ Reed (Harvard Medi-
cal School, Boston, Massachusetts) and M+T+ McNally (Med-
ical College of Wisconsin, Milwaukee, Wisconsin)+ Following
trimming with KpnI and XbaI, the insert fragments were cloned
into pDsx-K/X, to produce chimeric plasmids with TRa se-
quences cloned downstream of dsx exon 4+ Four plasmids
were constructed+ pDsx-SE80, pDsx-SE80G/A, and pDsx-
SE80G/U include the SEa2 inserts from pErbA(SE80),
pErbA(SE80)G/A and pErbA(SE80)G/U, respectively+ pDsx-
80SE80 contains the SE80 extended by an additional 80 nt
upstream of the Bsu36I site for a total insert length of 160 nt+
These inserts were generated by PCR using sense primers
containing a KpnI site at the 59 end and antisense primers
located downstream of the XbaI site in the corresponding
pErbA derived constructs+ The fragments used to construct
pDsx-SE80 and pDsx-SE80G/U were also cloned into pDsx-
X/K in the reverse orientation to create pDsx-SE80(R) and
pDsx-SE80G/U(R), respectively+ Sequences of all cloned
PCR-generated inserts were confirmed by DNA sequencing+
Cell culture and in vivo RNA analysis
COS-1 and HEK 293 cells were maintained as previously
described (Hastings et al+, 1997, 2000)+ Twenty-four hours
prior to transfection, logarithmically growing COS-1 or HEK
293 cells were replated at a density of 5 3 105 or 1+5 3 106
cells per 90-mm plate+ Cells were transfected with 5 mg of
plasmid DNA per plate using the calcium phosphate proce-
dure and total RNA was harvested 48 h posttransfection by
Nonidet P-40 lysis (Sambrook et al+, 1989)+ RNAse protection
assays were carried out and quantitated using probes and
procedures previously described (Hastings et al+, 1997, 2000)+
In vitro splicing
All pa2 plasmids were linearized with EcoRI and transcribed
with SP6 RNA polymerase to generate RNA substrates, as
described previously (Munroe & Lazar, 1991)+ pHB500 was
cut with BamHI and transcribed with T7 RNA polymerase to
obtain the globin transcript as previously described (Munroe,
1988)+ The chimeric pDsx-SE80 plasmids were linearized
with XbaI and transcribed with T7 RNA polymerase+ pDsx-
X/K and pDsx-ASLV were cut with XbaI and MluI, respec-
tively, and transcribed with T7 RNApolymerase+ In vitro splicing
assays were performed with HeLa nuclear extract as previ-
ously described using the specific conditions described for
splicing b-globin, TRa, and dsx transcripts (Munroe, 1988;
Munroe & Lazar, 1991; Tian & Maniatis, 1993)+ Competitor
RNAs SE80 and SE80G/U were made by transcribing pDsx-
SE80(R) and pDsx-SE80G/U(R), respectively, with SP6 RNA
polymerase after linearizing with XbaI+ These transcripts
were 133 nt in length, including the 80-nt SE80 sequence
and 53 nt of flanking polylinker sequence+ Another set of
SE80 and SE80G/U competitor RNAs was made by tran-
scribing pErbA(SE80)DHB and pErbA(SE80)G/UDHB with
T7 RNA polymerase after linearizing with XbaI+ These tran-
scripts contained only 16 nt of a different flanking sequence+
Nonspecific competitor RNA was transcribed from pDsx lin-
earized with HaeIII and transcribed with SP6 to generate a
130-nt RNA transcript containing 85 nt of antisense dsx se-
quence and additional polylinker sequence identical to that in
the SEa2 competitor RNAs+ Competitor RNAs were uni-
formly labeled with 3H-CTP to facilitate quantitation based on
the specific base composition of each transcript+ The cap
analog m7GpppG was incorporated into the 59 end of each
splicing substrate, but omitted from the competitor RNAs+
Competition experiments were performed by preincubating
competitor RNAs with HeLa nuclear extracts for 10 min at
30 8C prior to adding the 32P-labeled substrate+ RNA prod-
ucts were extracted, precipitated, subjected to electropho-
resis in polyacrylamide/urea gels, and quantitated on an
AMBIS radioanalytic imaging system as previously described
(Munroe, 1988; Hastings et al+, 1997)+ The splicing efficiency
was calculated as the percentage of fully spliced RNA divided
by the sum of spliced products and the remaining unspliced
pre-mRNA after correcting for length and base composition+
RNA substrates SE80, SE60, SE50, SE40, SE60CCA, and
SE60G/T used in splicing, UV-crosslinking, and immunopre-
cipitation reactions in Figures 6C and 9 were prepared by
PCR of pErbA(SE80) with a sense primer that includes the
T7 promoter (TAATACGACTCACTATAGGG) followed by the
last two G residues of the Bsu36I site and an antisense
primer within exon 10+ The PCR products were linearized
with XbaI and transcribed with T7 RNA polymerase to give
RNAs with no flanking sequences+ The crosslinking pattern
of SE80 was identical to that of SE80 transcripts from plas-
mids linearized with XbaI+
RNA–protein crosslinking
Ten nanomoles 32P-labeled SE80 RNA transcribed from
pErbA(SE80)DHB were incubated under splicing conditions
(without polyvinyl alcohol) in the presence or absence of a
1+25- to 5-fold molar excess competitor RNA with HeLa cell
nuclear extract, S100 fraction, or an SR protein fraction
(Krainer et al+, 1984; Krainer & Maniatis, 1985; Zahler, 1999)+
After 30 min at 30 8C, the reactions were put on ice and
exposed to 254 nm UV light using a Spectronics XL-1000
UV crosslinker at a setting of 18 mJ/cm2+ Samples were
digested with RNase A (10 mg) and RNase T1 (100 U) for
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15 min at 37 8C+ Crosslinked proteins were analyzed by
SDS polyacrylamide gel electrophoresis, followed by auto-
radiography+ Sets of SE80 competitors, with long, short, or
no flanking regions, were used with identical results in UV-
crosslinking experiments+
Immunoprecipitation of crosslinked proteins
For immunoprecipitation of SF2/ASF and hnRNP H and F
bound and UV crosslinked to RNA, protein A-Sepharose beads
(15 mL; Pharmacia) were bound overnight at 4 8C to either an
SF2/ASF specific antibody, mAb96, or to a maltose-binding
protein-specific antibody, mAb105 control antibody (Hana-
mura et al+, 1998)+ Antibodies specific for hnRNP H (a gift of
D+ Black, University of California, Los Angeles/Howard Hughes
Medical Institute; Chou et al+, 1999), hnRNP F, and pre-
immune serum (a gift from C+ Milcarek, University of Pitts-
burgh) were bound to protein A-Sepharose beads for 3 h at
4 8C+ The beads were washed three times with immunopre-
cipitation buffer (50 mM Tris-HCl, pH 7+5, 150 mM NaCl, and
0+05% NP-40)+ UV-crosslinking reactions, performed as de-
scribed above except crosslinked at 1+8 J/cm2, were added
to the antibody-bound beads and mixed for 2 h at 4 8C fol-
lowed by three washes in immunoprecipitation buffer+ Im-
munoprecipitated proteins were eluted from the beads by
boiling for 5 min in SDS-PAGE loading buffer and were re-
solved by SDS-PAGE+
Northwestern and western blot analysis
HeLa nuclear extract, S100 extract, total HeLa SR proteins,
recombinant proteins SF2/ASF, expressed in Escherichia coli
and purified (Screaton et al+, 1995), and baculovirus-expressed
SC35 were run on a 12% SDS polyacrylamide gel and elec-
troblotted onto Protran nitrocellulose membrane+ Northwest-
ern blots were blocked by incubating 1 h in 5% nonfat dry
milk in 25 mM NaCl, 1 mM EDTA, 1 mM DTT, 10 mM HEPES,
pH 8+0+ RNA binding was carried out by incubating the blot
with 32P-labeled SEa2 RNA (106 cpm) in RNA binding buffer
(50 mg/mL tRNA, 2+5% nonfat dry milk, 50 mM NaCl, 10 mM
MgCl2, 1 mM EDTA, 1 mM DTT, 10 mM HEPES, pH 8+0)+
After a 30-min incubation at room temperature, samples were
washed three times in RNA binding buffer+ For western blots,
membranes were blocked by overnight incubation in 5% non-
fat dry milk in TBST (10 mM Tris-Cl, pH 8, 150 mM NaCl, and
0+05% Tween) and washed with TBST+ Blots were probed
with SF2/ASF monoclonal antibody mAb96 (1:20) for 1 h,
washed with TBST, incubated with HRP-conjugated goat anti-
mouse, and developed with ECL western blotting detection
reagent (Amersham)+
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